Sansbury Leah B, Millikan Robert C, Schroeder Jane C, North Kari E, Moorman Patricia G, Keku Temitope O, de Cotret Allan Rene', Player Jon, Sandler Robert S
Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892-8325, USA.
Cancer Causes Control. 2006 Apr;17(3):257-66. doi: 10.1007/s10552-005-0417-0.
The inducible Cyclooxygenase (COX)-2 enzyme plays an important role in inflammation and carcinogenesis. Recent reports suggest that single nucleotide polymorphisms (SNPs) in the COX-2 gene may alter enzyme function and in turn modify an individual's risk of colon cancer. We explored the association between the COX-2 Val511Ala SNP and risk of colon cancer among 240 African American cases and 326 African American controls in a population-based, case-control study in North Carolina.
We used unconditional logistic regression models to determine the odds ratios (ORs) for genotype and risk of colon cancer.
We observed a non-statistically significant inverse association between any Ala COX-2 genotype and risk of colon cancer (OR = 0.62, 95% CI: 0.33, 1.16) among African Americans. The inverse association was present among non-regular NSAID users, use < or = 3 times/week, (OR = 0.66; 95% CI: 0.32, 1.37) and regular NSAID users, use > or =3 times/week for > or =3 months, (OR = 0.41; 95% CI: 0.11, 1.54).
Our results suggest that the COX-2 Val511Ala SNP does not antagonize the effect of NSAIDs on colon cancer risk and provides support that NSAID use and the COX-2 Val511Ala SNP may contribute to a reduced risk of colon cancer among African Americans.
诱导型环氧化酶（COX）-2在炎症和致癌过程中起重要作用。最近的报告表明，COX-2基因中的单核苷酸多态性（SNP）可能改变酶的功能，进而改变个体患结肠癌的风险。在北卡罗来纳州一项基于人群的病例对照研究中，我们探讨了240例非裔美国病例和326例非裔美国对照中COX-2 Val511Ala SNP与结肠癌风险之间的关联。
我们使用无条件逻辑回归模型来确定基因型与结肠癌风险的比值比（OR）。
我们观察到，在非裔美国人中，任何Ala COX-2基因型与结肠癌风险之间存在非统计学显著的负相关（OR = 0.62，95%置信区间：0.33，1.16）。在非规律使用非甾体抗炎药（NSAID）的人群（每周使用次数≤3次）中，这种负相关存在（OR = 0.66；95%置信区间：0.32，1.37），在规律使用NSAID的人群（每周使用次数≥3次且持续≥3个月）中也存在（OR = 0.41；95%置信区间：0.11，1.54）。
我们的结果表明，COX-2 Val511Ala SNP不会拮抗NSAIDs对结肠癌风险的影响，并支持NSAID的使用和COX-2 Val511Ala SNP可能有助于降低非裔美国人患结肠癌的风险。
